This archived overview describes the early commercial interest in CBD in Switzerland. The earlier article cited a market estimate of CHF 60 million for 2017 and a forecast of CHF 320 million by 2027. It did not identify the underlying datasets or forecast methodology. These amounts are retained as historical claims, not verified market turnover, government revenue or current investment projections.
Switzerland attracted attention as a location for hemp and CBD businesses, but the earlier description of it as Europe’s best market was a promotional judgement, not a documented international ranking. Commercial prospects and legal permission are different questions: a favourable view of the market does not establish that a particular product or business model is compliant.
The following 7 sections retain the original topics while distinguishing historical market commentary from the product-specific legal requirements described in official Swiss guidance.
1. Swiss law on CBD
Swiss guidance distinguishes cannabis with less than 1% total THC from cannabis at or above that threshold. The boundary is not inclusive: a product at 1% is not in the below-threshold category. The Federal Office of Public Health explains the distinction between narcotics control and the other laws that apply to different uses.
CBD itself is not subject to the Swiss Narcotics Act, but that does not authorise every finished product containing it. Composition and intended use still matter. Other European countries have their own narcotics and product rules; Swiss treatment of CBD is not evidence that most countries have granted a general permission for all CBD products.
The earlier comparison between a 0.2% limit in other countries and Switzerland’s 1% boundary mixed different regulatory purposes. A cultivation threshold, a food contaminant limit and a rule for a medicine are not interchangeable. Swiss guidance on low-THC cannabis expressly notes that products outside narcotics control cannot be sold or advertised without regard to other legislation.
THC limits do not establish an optimal harvest stage or prove medicinal benefit. The earlier article linked later harvesting to stronger treatment effects but supplied no cultivar, compositional or clinical evidence for that comparison. A grower must distinguish the requirements governing the crop from the evidence and authorisations required for a finished medicinal product.
The original account attributed a favourable assessment of Swiss CBD policy to Josh Stanley, describing the government as forward-thinking and interested in medical and recreational potential. No dated interview or primary quotation was linked. This remains attributed historical commentary, not a government endorsement of every CBD use or a guarantee that businesses will be safe, profitable or free from regulatory change.
The earlier blanket claim of a three-year jail sentence for every purchase, sale, production, possession or use of cannabis above 1% THC is not an accurate statement of Swiss law: the activity, authorisation and circumstances matter. Nor is 18 a universal purchasing rule for every CBD category; the product-specific youth-access rules are explained below. Driving is a separate question. The FOPH-commissioned CBDrive study describes a threshold of 1.5 micrograms of THC per litre of whole blood and reports that low-THC cannabis can exceed it. A product’s percentage does not predict an individual’s blood concentration or establish fitness to drive. The earlier reference to the World Health Organization also did not create an exemption from Swiss law: zero-THC wording does not remove requirements for food, medicines, cosmetics or consumer safety.
2. Medical cannabis in Switzerland: historical and current access
The Swiss Narcotics Act’s 2011 revision enabled exceptional authorisations for limited medical use of prohibited narcotics. The earlier article’s description of special FOPH permission belongs to that historical framework; it should not be read as the current prescribing procedure or as a permit requirement for every low-THC CBD product.
The earlier account compared people using CBD with and without permits in 2017 and attributed this to serious-illness criteria and lengthy administration. It supplied no dataset establishing that comparison or proving that patients were bypassing the law. Consumer CBD products and prescribed cannabis medicines are distinct categories, so counts from one cannot establish access or unauthorised use in the other.
The subsequent reform is now a completed change, not simply a review assigned to the Home Affairs Ministry. Since 1 August 2022, physicians have no longer needed an FOPH exceptional authorisation to prescribe cannabis medicines. The FOPH’s medical-cannabis guidance explains that treatment is the prescribing clinician’s responsibility and that medical-cannabis production and trade remain subject to Swissmedic controls.
This change concerns access to cannabis medicines; it does not make every retail CBD preparation an authorised treatment. The earlier description of Switzerland as innovative was an assessment of policy and business prospects. Product quality, the applicable medicinal-product requirements and the circumstances of an individual prescription remain separate considerations.
3. Hemp cultivation: the scope of licensing requirements
The earlier article dated hemp legalisation to August 2016, but did not identify a measure establishing that claim. The Federal Office for Agriculture’s hemp guidance instead documents the removal of hemp provisions from seed legislation from 1 January 2021. Hemp below 1% THC can be used agriculturally; the stated boundary must not be read as permitting a crop at or above it outside the relevant controls.
The Federal Office for Agriculture does not issue hemp-cultivation licences. That limited statement is not a waiver of all requirements: plant-health rules still apply, and marketable hemp plants require a plant passport. For controlled cannabis grown for medical purposes, Swissmedic describes establishment and individual cultivation licences. Foreign investors therefore cannot infer an unrestricted, licence-free operation merely from the agricultural position.
4. CBD product categories in Switzerland
Swiss businesses have offered CBD in forms including cigarettes, cosmetics, tinctures, vaporiser liquids, supplements and oils, both online and in shops. That variety is not proof that every example is lawfully marketable. Being 18 or over and choosing a product below 1% THC does not replace a category assessment. The joint official implementation guide assesses products by their composition, intended use and presentation, rather than the CBD label alone.
CBD-containing hemp cigarettes are recognised as herbal smoking products in the tobacco-products framework. The earlier claims that Switzerland held a world record for inventing them and that they had reduced tobacco consumption were not supported by comparative or consumption data. Their availability must not be presented as evidence of a health benefit or of successful smoking cessation; Swiss tobacco-products rules include health-protection requirements.
Foods illustrate why these distinctions matter. The Federal Food Safety and Veterinary Office distinguishes traditional hempseed foods from cannabinoid-containing extracts and cannabinoids requiring novel-food authorisation. A compliant seed oil is not evidence that a CBD-enriched oil or supplement has the same status. Cosmetics and medicines must be assessed under their respective requirements, not by borrowing a food or smoking-product classification.
5. Selling CBD products in Switzerland
Selling CBD is not governed by a universal exemption from licensing. Business registration and tax obligations must be distinguished from product authorisation, notification, labelling and the rules for the activity concerned. Registration alone does not make an otherwise non-compliant product marketable, and the requirements for a retail shop are not automatically those for manufacturing a medicine.
The nationwide minimum supply age of 18 applies to products covered by the Tobacco Products Act, including CBD-containing herbal smoking products and electronic cigarettes. The FOPH’s implementation FAQ dates that rule to 1 October 2024 and explains that cantons may also require sellers to register or obtain permission. This must not be extended into a universal age or licensing rule for all CBD cosmetics, foods and medicines.
Tax treatment also depends on classification. The Swiss customs authority’s tobacco-tax guidance covers specified ready-to-use tobacco products and substitutes; the earlier reference to CBD cigarettes should not be applied automatically to every hemp flower, oil or other preparation. Products below the 1% narcotics threshold are not thereby exempt from applicable taxes, and a tax classification is not itself permission to sell the product.
For imports and exports, the product, shipment documentation and destination rules must be considered separately. The earlier reference to 0.2% THC was not a universal export standard. Swiss guidance on low-THC imports requires evidence of composition for the actual shipment; compliance with a Swiss threshold does not establish that a receiving country permits the same product or use.
Switzerland offers routes for compliant hemp and CBD businesses, but the market is not unrestricted or free of entry conditions. Cultivation, processing, medicinal use, food sale and smoking products involve different requirements, and the activity must be assessed in the category in which it will actually operate.
6. Historical CBD market estimates and their limits
The original market discussion described the United States as the largest CBD and hemp market and cited forecasts of $591 million before 2019 and $2.1 billion in 2020, calling this a 700% increase from 2016. No underlying report, market definition or baseline was linked. These are historical forecasts reproduced from the earlier article, not verified outcomes or a current market comparison.
The same account described Switzerland’s CBD industry as roughly 3 years old and placed its starting value at CHF 60 million in 2017, approximately US$59.5 million. It cited annual growth of 39% and a projected CHF 320 million, approximately US$318 million. The annual rate and the longer-term total stated above do not form a consistent compounded forecast. The original dollar equivalents are retained as historical approximations, not recalculated exchange rates, and the account does not establish when all Swiss hemp activity began.
The projected CHF 83 million, approximately US$82 million, for the end of 2018 was also an estimate rather than an observed result. It must not be presented as proof of sales, tax receipts or consumer spending. A forecast can be evaluated only with its stated period, market coverage and underlying method, which were not supplied here.
The original comparison used populations of 328 million in the United States and 8.4 million in Switzerland to claim that Switzerland spent five times more on CBD in 2018. Population adjustment would concern spending per person, not total national spending; moreover, the article mixed estimates and periods without a comparable observed dataset. Those historical population figures do not establish the claimed spending difference.
These figures explain the optimism expressed in the earlier article, but they do not demonstrate uninterrupted growth or establish today’s market size. A current assessment would require dated, comparable evidence identifying which products, sales channels and geographic markets were measured, rather than carrying the old projections forward as facts.
7. Shipping of CBD from Switzerland through Europe or to Germany
Shipping a CBD product from Switzerland to a European destination is not automatically lawful because that country permits some CBD uses. The Swiss customs guidance on restrictions distinguishes import, export and transit requirements, including cases requiring authorisation or further information. The applicable rules must be checked for the particular goods and route.
The earlier suggestion that 0.2% THC, or 0.2% or less, guarantees compliance across Europe is not reliable. Destinations may distinguish plant material, extracts, foods, cosmetics and medicines and apply different tests or authorisation requirements. A seller must assess the actual product and destination rather than treating a single percentage as a cross-border permission.
Switzerland is outside the European Union, so goods dispatched from there into the EU, including Germany, involve import formalities. The European Commission explains that online imports require a customs declaration and may involve import VAT, duties or handling charges. VAT can be collected at purchase or on delivery under the applicable arrangement; payment of tax does not override product restrictions.
Customs enquiries can delay a parcel, and restricted or incorrectly declared goods may not be released. The earlier assurance that delivery always arrives, or that unspecified steps would eliminate delays, was not supported by shipment evidence. Delivery timing and release depend on the individual consignment and the competent authorities’ decisions.
A compliant export therefore requires both a lawful product and the necessary border formalities. This historical overview does not promise delivery, clearance or a fixed landed price for any order. The seller’s actual shipping terms and the destination’s requirements must be checked for the shipment in question.
